



RadioOnkologie



Behandeln  
Forschen  
Lehren



GERMAN  
CANCER RESEARCH CENTER  
IN THE HELMHOLTZ ASSOCIATION

UniversitätsKlinikum Heidelberg

# Clinical Results of Carbon Ion Radiotherapy: *The Heidelberg Experience*

Stephanie E. Combs, MD

Department of Radiation Oncology  
University of Heidelberg, Germany



# Carbon ion RT at GSI

- Active beam delivery (raster scan technique)
- Online beam verification with PET
- Biologic plan optimization
- Treatment planning software TRiP
- Physical treatment planning and dosimetry
- Preclinical research (cell and animal experiments)
- Clinical research

## Cooperation:

- GSI (Kraft and Co-workers)
- Research Center Rossendorf (Enghardt and Co-workers)
- DKFZ, Div. of Physics in Medicine (Schlegel, Jäkel, Karger and Co-workers)
- DKFZ, Div. of Radiation Oncology (Huber and Co-workers)
- University of Heidelberg and HIT (Debus and Co-workers)





# Patient setup and treatment at GSI


PET-camera

X-ray system

Beam line



# 3D Active beam scanning at GSI: Principle of raster scanning







## Intensity Controlled Raster Scanning with heavy charged particles:



### Clinical Experience:

Protons:

PSI, CH: > 350 patients

Carbon-ions:

GSI, D: 407 patients


Clinical Feasibility

Verification film irradiated with C-12 in 1996



# Carbon Ion Radiotherapy at GSI

n=407





## Introduction

### Chordomas

- originate from embryonal remnants of the notochord
- 1-4% of all malignant bone tumors
- 35% localized in the skull base region

### Chondrosarcomas

- 10% of all malignant bone tumors
- 5-12% localized in the head-and-neck region

**Central role of proton RT for the treatment of chordomas  
and chondrosarcomas of the skull base**



# Carbon ion RT in skull base chondrosarcomas



## Clinical Phase I/II trial 1998-2001

- Intensity-modulated carbon ion RT
- Active beam delivery
- Biological plan optimization
- Stereotactic target point localization
- Total dose 60 CGE, fractionation 7 x 3.0 CGE
- BED 75 CGE (75-96 CGE)





# Immobilization for Precision Radiotherapy









# Patient positioning and stereotactic definition of treatment volume

contrast-enhanced CT and MRI scans

image fusion

target delineation







# Patients' characteristics

- n=54 chondrosarcoma patients treated between 1998 and 2005
- median age 46 years (6-74)
- m:w = 1:1
- macroscopic tumor in all patients
- WHO-Classification (G1-3, EMC, mesenchymal)

G1	23 (42.6%)
G2	12 (22.2%)
G1/2	5 (9.3%)
well diff.	14 (25.9%)
- Myxoid 7
- Mesenchymal 1




# Carbon ion radiotherapy for skull base chondrosarcomas



- 54 patients analyzed
- GD = 60 Gy E, 7 x 3Gy E/week


# Carbon ion radiotherapy for skull base chondrosarcomas

## Local Control



96.2% and 89.8% @ 3 and 4 years

## Overall Survival



5-years OS 98.2%

2 recurrences (mesenchymaler histology):  
n=1 in-field  
n=1 field border

# Particle therapy for chondrosarcomas


Author, year	n	RT	dose	LC
Rosenberg, 1999	200	Prot. (+ Phot)	72.1	98% / 5y
Hug, 1999	25	Protons	70.7	23/25 / 5y
Weber, 2005	11	Protons	68	100% / 3y
Castro, 1994	27	He	65	78% / 5y
Noel, 2003	18	Prot + Phot	67	85% / 3y
Schulz-Ertner, 2007	54	C12	60*	89% / 4y

\*FX 75 CGE







**Prior to C12:  
rt. hemianopsia  
60 GyE**




**PR**



**12 months  
hemianopsia**



**20 months  
moderate  
improvement**




## **Carbon ion RT in skull base chordoma prospective phase I/II trial (1998-2001)**


- 1998 – 2005, n=96 with macroscopic tumor
- Total dose 60 – 70 CGE, weekly fractionation 7 x 3.0 CGE ( $\alpha/\beta=2$  Gy)  
corresponding to BED of 75-96 CGE
- Intensity-modulated carbon ion RT, active beam delivery
- Biologic plan optimization
- Prospective clinical phase I/II trial: 43 patients, 53 further patients
- Median FU 31 months
- Regular FU with MRI scan




# Carbon ion radiotherapy for skull base chordomas




**Local Control**



**Overall Survival**



**Dose-response relationship**





# Chordoma of the Skull Base

patient with intended left lateral gaze




**Before RT:  
diplopia**



**6 Months after RT  
resolution of diplopia**



# Motivation: Dose Response Relationship Radiotherapy of Skull Base Chordomas




[Schulz-Ertner, IJROBP 2007]



## Carbon ion Radiotherapy at GSI

- Clinical feasibility and safety was shown
- excellent local control rates for chordomas/chondrosarcomas of the skull base with low toxicity
- superior results for photon treatment for adenoidcystic carcinomas (boost treatment)
- currently study on prostate cancer (boost treatment)
- further studies on carbon ion RT required
- for skull base chordomas and chondrosarcomas, randomized trials comparing proton and carbon ion RT are needed



## **PTCOG 48: September 21<sup>st</sup> – September 25<sup>th</sup>, 2009**

48th Annual Meeting of the Particle Therapy  
Co-Operative Group (PTCOG)

University Hospital of Heidelberg,  
Department of Radiation Oncology,  
Heidelberg Ion Therapy (HIT) Center Heidelberg, Germany



## Contact Information

### Meeting homepage

- meeting venue
- programme updates
- hotel and travel
- sightseeing and entertainment




**[www.klinikum.uni-heidelberg.de/ptcog2009](http://www.klinikum.uni-heidelberg.de/ptcog2009)**

**Local organizing committee – Send us and e-mail!**



**[ptcog.2009@med.uni-heidelberg.de](mailto:ptcog.2009@med.uni-heidelberg.de)**



## **PTCOG 48: September 21<sup>st</sup> – September 25<sup>th</sup>, 2009**

48th Annual Meeting of the Particle Therapy  
Co-Operative Group (PTCOG)

University Hospital of Heidelberg,  
Department of Radiation Oncology,  
Heidelberg Ion Therapy (HIT) Center Heidelberg, Germany